RNTX
$1.42
Post-MarketAs of Mar 17, 8:00 PM UTC
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.42
Potential Upside
5%
Whystock Fair Value$1.49
Price
UndervaluedFair ValueOvervalued
Fundamentals
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-83.28%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.70
